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Abstract: Co-delivery of cancer therapeutics improves efficacy and encourages synergy, but delivery
faces challenges, including multidrug resistance and spatiotemporal distribution of therapeutics.
To address these, we added paclitaxel to previously developed acoustically labile, oxygen-core,
surfactant-stabilized microbubbles encapsulating lonidamine, with the aim of developing an agent
containing both a therapeutic gas and two drugs acting in combination. Upon comparison of unloaded,
single-loaded, and dual-loaded microbubbles, size (~1.7 µm) and yield (~2 × 109 microbubbles/mL)
(~1.7) were not statistically different, nor were acoustic properties (maximum in vitro enhancements
roughly 18 dB, in vitro enhancements roughly 18 dB). Both drugs encapsulated above required
doses calculated for head and neck squamous cell carcinoma, the cancer of choice. Interestingly,
paclitaxel encapsulation efficiency increased from 1.66% to 3.48% when lonidamine was included.
During preparation, the combination of single drug-loaded micelles gave higher encapsulation
(µg drug/g microbubbles) than micelles loaded with either drug alone (lonidamine, 104.85 ± 22.87
vs. 87.54 ± 16.41), paclitaxel (187.35 ± 8.38 vs. 136.51 ± 30.66). In vivo intravenous microbubbles
produced prompt ultrasound enhancement within tumors lasting 3–5 min, indicating penetration
into tumor vasculature. The ability to locally destroy the microbubble within the tumor vasculature
was confirmed using a series of higher intensity ultrasound pulses. This ability to locally destroy
microbubbles shows therapeutic promise that warrants further investigation.

Academic Editor: Iolanda De Marco
Received: 7 March 2022
Accepted: 7 April 2022

Keywords: ultrasound contrast agent; microbubbles; theranostic agents; ultrasound-triggered drug
delivery; dual drug loading; surfactant; oxygen delivery

Published: 12 April 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in

1. Introduction

published maps and institutional affil-

Multidrug resistance (MDR) restricts chemotherapeutic power and presents a major
impediment in the treatment of cancer, with MDR believed to be the cause of treatment
failure in over 90% of patients with metastatic disease [1]. Classical MDR results from
an overexpressed, energy-dependent, and unidirectional drug efflux pump that is cellmembrane bound and composed of a transmembrane glycoprotein (P-gp) [2,3]. We are
interested in head and neck cancer, and various studies have implicated P-gp expression
in MDR in these cancers [4–7]. Multiple types of non-ionic surfactants and polymers
have been shown to inhibit the P-gp efflux pump, including Cremophor EL, D-alphatocopherol-poly (ethylene glycol 1000) succinate (TPGS), Tween80, and various chitosan
derivatives. This inhibition can in turn result in increased intracellular concentrations of
chemotherapeutics such as paclitaxel (PTX), and this results in enhanced therapeutic efficacy
against MDR tumors [2]. Therapeutics can also target MDR and the P-gp efflux pump by
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halting intracellular adenosine triphosphate (ATP) production capabilities and promoting
pro-apoptotic factors. These include colchicines, 3-bromopyruvate, and lonidamine (LND).
Lonidamine, in particular, has been shown to be able to inhibit the hexokinase enzyme that
is pivotal to mitochondrial function, making it attractive in therapies that treat multiple
types of cancer [2]. Importantly, LND is also able to sensitize tumors to radiotherapy and
photodynamic therapy [8]. Huang et al. point to the unique characteristics of tumors’
energy metabolism and the Warburg effect and hence suggest its advantages of selectivity
and lack of overlapping adverse effects [9].
A frequent precursor to the development of MDR is hypoxia [10], which is prevalent
in up to 70% of head and neck cancers [11,12]. Hypoxia can arise from a disruption of
tumor microcirculation, giving rise to large diffusion distances (>70 µm) that oxygen must
travel before it reaches the cell, a phenomenon known as chronic or diffusion-limited
hypoxia. Hypoxia is especially problematic as it allows solid tumors to become resistant to
radiotherapy and chemotherapy and hastens tumor progression [12]. Oxygen is a powerful
chemical radiosensitizer and plays a vital role in permanently securing the DNA damage
caused by radiotherapy. The radiation dose needs to be increased almost three-fold in the
absence of oxygen compared to normal levels just to keep equivalent efficacy. Hypoxia may
increase radiation resistance by increasing the levels of heat shock proteins and decreasing
apoptotic potential, both of which have been linked to radiation resistance and proteome
changes that strongly impact tumor propagation [13,14]. Fortunately, very little oxygen
is needed to sensitize hypoxic tumors to radiotherapy [15]. Hypoxia also interferes with
chemotherapy due to indirect effects associated with increased glycolysis and extracellular
acidosis [12]. Regulation of hypoxia in the tumor also plays a key role in other therapies,
for example in photodynamic therapy, which relies on the generation of reactive oxygen
species (ROS) to kill cancer cells, a mechanism that is severely restricted by hypoxia [16].
Combinatorial therapy is especially effective in cancer as it can target different key
pathways in a tumor and often results in lowering the required therapeutic dosage of a given
drug [17,18]. One such combination therapy for MDR involves the dual delivery of PTX and
LND. The combination of LND’s role in intracellular ATP suppression and P-gp inhibition
leads to increased accumulation of intracellular PTX, which overall leads to the induction of
apoptosis in tumor cells [2]. Multimodal therapies that combine different modes of therapy
such as chemotherapy and radiotherapy (known as chemoradiotherapy) [19,20] are often
highly effective. These result in “super-additive” effects where the combined therapy is
much stronger and more efficacious than a single type [21]. For example, Puiu et al. even
suggested the dual use of magnetically targetable SPIONs based on magnetite (Fe3 O4 )
nanoparticles’ surfaces modified with β-cyclodextrin (CD) and PTX-guest-host inclusion
complexes [22].
Several groups have investigated the dual delivery of PTX and LND as a combination therapy to target and reverse MDR in cancers [2,23]. However, to our knowledge,
addressing the additional problem of relieving hypoxia has not also been considered.
Previously, our group designed an oxygen core, surfactant-stabilized microbubble
named SE61O2 which is composed of a sorbitan monostearate and TPGS shell (Figure 1).
Toxicity studies using microbubbles with this and very similar shell chemistry have demonstrated the agent is non-toxic and well tolerated [24,25]. This microbubble acts as an
ultrasound contrast agent for enhanced imaging of tumors, as well as a delivery vehicle of
oxygen for the sensitization of hypoxic breast tumors for radiotherapy [26].
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2. Methods
2.1. Materials
The drug LND was purchased from Millipore Sigma (Allentown, PA, USA) and PTX
from LC Laboratories (Woburn, MA, USA). Materials for microbubble preparation included
TPGS, (Millipore Sigma, Allentown, PA, USA), sorbitan monostearate (Montane 60 PHA
Premium), a gift from Seppic (Fairfield, NJ, USA), octafluropropane (OFP) Specialty Gases
of America (Reno, NV, USA), oxygen gas from Airgas (Radnor, PA, USA), and passed
through a sterile 0.22-micrometer Nalgene filter (Nalge Nunc International, Rochester, NY,
USA) at an initial flow rate of 50 mL/min for 5–10 s then 20 mL/min for 1 min prior to use.
All other chemicals were from Millipore Sigma (Allentown, PA, USA) and used as received.
2.2. Unloaded SE61O2 Microbubble Fabrication
Unloaded microbubbles were prepared by a previously described method [34]. Briefly,
micelles were formed by heating 1.288 g of TPGS dissolved in 25 mL of 37 ◦ C phosphatebuffered saline (PBS) and placed on a stir plate for ~30 min. In parallel, 1.464 g of sorbitan
monostearate and 1.5 g of NaCl in 25 mL PBS solution were autoclaved (Yamato Scientific
Co., Ltd., Tokyo, Japan) for 35 min at 125 ◦ C to aid in dispersion. Initial micelle formation
was found in a previous study to generate over double the microbubble yield [34]. The
autoclaved solution was immediately added to the TPGS micelle solution and allowed to
cool to room temperature under continuous mixing. The mixture was then placed on an
ice bath and purged with PFC gas for 1 min. The mixture was then sonicated under PFC
purging, using a 0.5 inch probe horn (Misonix, Inc., Farmingdale, NY, USA), at 20 kHz for
3 min at 110 W to generate the microbubbles. The microbubble mixture was then placed in
a 250 mL separatory funnel for gravity separation, discarding the bottom layer containing
unused surfactant, and the top foam layer, and retaining the middle, microbubble layer.
The microbubbles were washed a total of three times over a 4–5-h period, in increments
of 1–1.5 h using 50 mL of 4 ◦ C PBS in each wash. After the last wash, microbubbles were
collected and diluted in a 1:1 (v/v) ratio with 10% (w/v) glucose to provide lyoprotection.
The microbubbles were then transferred in 2-milliliter aliquots to 10-milliliter lyophilization
vials (Type I AMB Glass, Duran Wheaton Kimble, Millville, NJ, USA), capped with rubber
stoppers (Duran Wheaton Kimble, Millville, NJ, USA), and placed in an ice bath consisting
of a 1:1 (v/v) water-propylene glycol (Haake D1 and G, Bacchus Marsh, Australia) at
−20 ◦ C. The microbubbles were gently shaken until frozen. The vials were then placed
on a specially designed pre-chilled shelf (−20 ◦ C) for at least 2 h. Lyophilization was
performed using a Virtis Benchtop freeze dryer 29 (Gardiner, NY, USA) for 20 h under a
condenser temperature of −70 ◦ C below 300 µbar pressure. The caps on the vials were
loosely sealed to the first groove during this process. The dried microbubbles were sealed
under a vacuum at the end of the cycle by depressing the stoppers prior to venting using a
piston. They were then removed and finally sealed around the stopper with parafilm and
stored at −20 ◦ C until use.
2.3. Single-Drug-Loaded SE61O2 Microbubble Fabrication
The quantity of drugs used in encapsulation was based on previous experience in our
lab and the calculation of estimated minimum drug encapsulation requirements at the site.
Estimation of minimum drug loading: For an assumed tumor volume of 65 mm3 , maximum injection volume in mice is 0.1 mL at an average microbubble concentration of
3.2 × 109 /mL, and 20% of microbubbles are destroyed at the tumor site after multiple circulatory passes [28,35]. Lonidamine metric is based on a minimum effective LND dose in tissue
culture of 3 µM; this translates to 3.13 µg LND/mL microbubble [36]. Paclitaxel Metric is
based on an effective dose of 1 µM in tissue culture, resulting in a desired minimum dose of
2.77 µg PTX/mL microbubble [37,38]. In preparations, 3.9 mg LND and/or 5 mg PTX were
added to each batch. For single-drug loading, 1.288 g of TPGS was dissolved in 25 mL of
37 ◦ C 1 × PBS for a short period (~10 min), after which the drug was added to the mixture
and allowed to incubate and establish equilibrium for 48 h at 37 ◦ C.
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2.4. Dual-Drug-Loaded SE61O2 Microbubble Fabrication
For dual loading, two different approaches were explored to more clearly identify
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Figure 2. Process for making drug-loaded SE61O2. (A) Individual drug-loaded micelles (LP1), (B)
(B) Micelles containing two drugs (LP2). Turquoise pentagon represents paclitaxel, red triangle
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2.6. Light Microscopy
An Olympus 1X71 microscope (Olympus Corporation, Tokyo, Japan) was used to
image the microbubbles and assess if the dual-drug loading caused any observable visual
changes to their general characteristics. Microbubbles were diluted in a 1:4 (v/v) ratio with
DI water before imaging. Microbubble images were processed using the Olympus CellSens
Standard software (Olympus Corporation, Tokyo, Japan).
2.7. In Vitro Acoustic Characterization
Lyophilized samples were charged with oxygen that was passed through a 0.2 µm
sterile filter at around 50 mL/min for 10 s. The microbubbles were then reconstituted in
2 mL of 0.5×PBS for acoustic characterization using a 5-megahertz ultrasound transducer
(part no. V309, Olympus, Waltham, MA, USA) focused inside a custom-built 50-milliliter
acrylic acoustic sample chamber submerged in a 10-gallon tank filled with water at 37 ◦ C,
following a previously published protocol [24]. The transducer had a focal length of
49.3 mm, diameter of 12.7 mm, center frequency of 5.15 MHz, peak frequency of 5.36 MHz,
and a −6 dB bandwidth of 82.46%. Pressure amplitudes were generated with a pulse
repetition frequency of 100 Hz at energy level 1 using a parametric pulse/receiver (model
5072PR). This results in a peak negative pressure of 0.25 MPa and a peak positive pressure
of 0.69 MPa. Signals were amplified by 40 dB and read using a LeCroy 9350A digital
oscilloscope (Chestnut Ridge, NY, USA). For acoustic enhancement, increasing volumes
of microbubbles were tested, replacing the PBS inside the chamber between each run and
graphing dB returned to the transducer against dose.
2.8. Flow Phantom Analysis
2.8.1. Imaging
Echogenicity and microbubble destruction were also assessed separately using an
in vitro closed-loop flow phantom setup (model 524, ATS Laboratories, Bridgeport, CT,
USA) and clinical scanner (S3000 Helx scanner, Siemens Healthineers, Mountain View, CA,
USA, with a 9L4 probe) at room temperature as previously described [39]. Samples of LP1type bubbles (drugs initially in separate micelles) were chosen since at the time of analysis
these were shown to have the highest drug encapsulation and would be taken on to future
in vivo experiments. Briefly, a known concentration of roughly 1.0 × 107 microbubbles
in 800 mL PBS was circulated at room temperature through the tissue-mimicking flow
phantom, passing through a 6-millimeter diameter vessel embedded in the device using
a peristaltic pump at 350 mL/min. Imaging of the microbubbles flowing through the
embedded vessel was performed in cadence pulse sequencing mode every 30 s for 20 min
(n = 3, for each formulation).
2.8.2. Stability Curves
The stability of the microbubbles in a clinically relevant ultrasound beam was determined by taking an image from the flow phantom every 30 s for 10 min. A region of interest
(ROI) was chosen on the contrast mode image and the mean enhancement measured within
that region and determined using ImageJ. This value, normalized to allow for microbubble concentration differences between samples, was used in equation 1 to determine the
enhancement (dB) at each time point and plotted against time.
dB = 20 log10
where
E = Mean enhancement returned to transducer
E0 = Baseline level enhancement.

E
E0

(1)
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2.9. Drug Loading Quantification
Quantification of PTX and LND was performed at Thomas Jefferson University. Samples were analyzed separately using two high-performance liquid chromatography (HPLC)
methods. Drug-loaded microbubbles were extracted in 4 mL methanol and filtered using a
0.45-micrometer-syringe filter; 1 mL of extracted samples was analyzed using HPLC.
Paclitaxel samples were analyzed on a Waters® HPLC Alliance 2695 separations
module system using a Phenomenex Luna 5 µm 100 Å, 100 × 4.6 mm column. Detection
was performed at 277 nm using a Waters® 2998 photodiode array detector (Milford, MA,
USA). The HPLC solvent consisted of a 30:70 (v/v) water/acetonitrile (ACN) ratio at a
0.5 mL/min flow rate. The total runtime was 5 min with a sample injection volume of
10 µL.
Lonidamine quantification was carried out using a Thermo Scientific, Dionex Ultimate
3000 UHPLC system (Waltham, MA, USA). Samples were analyzed using an Xbridge BEH
shield reverse phase C18 column (2.5 µm, 4.6 × 75 mm) and solvent ratio 50:50 water (with
0.1% formic acid [FA]) and ACN (with 0.1% FA) at a flow rate of 0.350 mL/min [40]. Detection was performed using a UV-visible spectrometer at 230 nm. The column temperature
was maintained at 30 ◦ C for analysis of samples. For LND, the total run time was 20 min
and the sample injection volume was 10 µL.
Encapsulation efficiencies of the drugs were calculated using the following Equation (2):
Encapsulation E f f iciency =

Mass o f Drug in MB (mg)
× 100%
Initial Mass o f Drug Aded (mg)

(2)

2.10. In Vivo Studies
All animal work was performed at Thomas Jefferson University under a protocol
approved by the local institutional animal care and use committee in accordance with
American Association for Laboratory Animal Science guidelines. To demonstrate initial
tolerability and the ability to detect and locally destroy dual-loaded microbubbles in vivo,
a brief series of imaging experiments were performed in athymic nude mice (two male,
one female; The Jackson Laboratory, Bar Harbor, ME, USA). Tumors were generated via
subcutaneous injection of 106 CAL27 oral human squamous cell carcinoma cells (ATTC,
Manassas, VA, USA) with 50 µL of Matrigel (Sigma) into the right hindlimb. Tumors were
monitored until reaching a total volume of approximately 150–500 mm3 before being used
for imaging experiments. Prior to imaging, animals were anesthetized with a mixture
of ketamine and acepromazine, and body temperature was maintained using a 37 ◦ C
heating pad.
Dual-loaded microbubbles made by the LP1 method—with drugs initially in separate
micelles—were suspended in room-temperature PBS as described above. A total injection
of 0.1 mL was then administered via a 24-gauge angiocatheter in the tail vein followed
by 0.05 mL saline flush. Continuous imaging in dual B-mode/cadence pulse-sequencing
contrast mode was acquired using a 10L4 transducer and Acuson Sequoia (Siemens Healthineers, MountView, CA, USA). Imaging was acquired at a depth of 3 cm and focal zone
of 1 cm. Low mechanical index (MI; 0.12) imaging was used to obtain non-destructive
visualization of microbubble perfusion into the tumor. Following peak enhancement, a
destructive pulse (4 s at MI = 1.4) was initiated to destroy microbubbles within the tumor
followed by 10 s of low-MI imaging to visualize reperfusion. This process was repeated
for the duration of contrast enhancement (approximately 3–4 min). Animals were then
monitored for at least 30 min for acute toxicity.
2.11. Statistical Analysis
All data are presented as a standard deviation about the mean. Acoustical data were
measured from three microbubble lots, with each repeated three times (n = 3). Bubble
counts and size data were obtained from one lot with each repeated three times (n = 3).
Microbubble average size and drug loading values with standard deviations were calcu-
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lated using Excel (Microsoft Office 365 Plus, Microsoft Corporation, Redmond, WA, USA).
Statistical significance for each type of drug loading between dual loading conditions was
determined using a one-way ANOVA with Tukey post hoc tests. Significance in acoustical
properties and bubble populations between drug-loading conditions was determined using
a one-factor MANOVA (Wilks’ Lambda). A significance level of α = 0.05 was used and
tests were run using the software Statistical Package for the Social Sciences (SPSS, Chicago,
IL, USA).
3. Results and Discussion
3.1. Incorporation of a Single Drug
Single drug (PTX or LND) loading on the SE61 microbubble was initially analyzed to
serve as a baseline for the dual-loaded microbubbles. Both LND and PTX were encapsulated
as described, initially mixing the drug into a TPGS 0.052% (w/v) solution for 48 h, creating
drug-loaded micelles before adding to the autoclaved sorbitan monostearate solution. This
efficiently created a final mixture with a 0.026% (w/v) TPGS and 0.029% (w/v) sorbitan
monostearate concentration that was then sonicated for microbubble fabrication. During
both these stages, the TPGS concentration remained above its critical micelle concentration
(CMC) of 0.02% (w/w), ensuring micelles were present and that the drug was ideally
encapsulated within them.
3.1.1. SE61O2 Microbubble Size Populations
Despite differences in chemical structure, molecular weight (LND 321, PTX 853.9),
and hydrophobicity (LND log P = 3.9–4., PTX log P = 7.4), separate incorporation of these
drugs into the SE61O2 microbubbles did not have a significant effect on microbubble size
population as measured by mean bubble size and total concentration (p = 0.86) (Table 1).
Representative size distribution profiles are given in the Supplementary Materials (Figure
S1) and show all groups had similar distributions. All microbubble groups had an average
diameter well below the requirement of <6 µm to pass through the vasculature.
Table 1. Effect of single-drug incorporation on microbubble size, concentration, and acoustic behavior.

Unloaded
LND-SE61O2
PTX-SE61O2

Diameter (µm)

Concentration × 109
(Microbubbles/mL)

Maximum Enhancement (dB)

Dose at Max
(MB/mL × 107 )

1.69 ± 0.10
1.74 ± 0.05
1.68 ± 0.08

3.30 ± 1.35
1.57 ± 0.62
2.29 ± 0.50

18.10 ± 0.52
18.70 ± 0.40
18.90 ± 0.18

4.94 ± 1.65
3.67 ± 0.91
3.81 ± 0.66

The ease of insertion was not surprising since both drugs are found to partition into
lipid monolayers [23,41]. All preparations were within the size range of less than 5 µm,
required for free passage through the pulmonary bed. Bubble size measurements were substantiated by light microscopy, presented in Supplementary Materials (Figures S2 and S3).
This confirmation is particularly relevant when measuring buoyant particles that could
influence methods of measurement dependent on Brownian motion, such as dynamic light
scattering; however, with our use of the Entegris AccuSizer® , which depends on single
particle optical sizing technology; the results were not subject to these buoyancy effects.
3.1.2. In Vitro Acoustic Characterization
Our in vitro tank testing of acoustic microbubbles served as an excellent method of
investigating differences in acoustic behavior among different preparations. While all
measures were taken to ensure we came close to in vivo conditions (temperature, pH, and
salt content of suspending medium; continuous stirring), these measurements are best used
for comparison purposes, although we have shown in the past that they closely mirror
in vivo measurements [42]. We considered two parameters—maximum dB achieved, and
the dose at which this maximum is obtained when evaluating acoustical properties. As with
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Table 2. Quantification of single-drug loading.

PTX SE61O2
LND SE61O2

Added Drug (mg)

µg Drug/mL
Microbubble

µg Drug/g
Microbubble

µMoles Drug/g
Microbubble

Encapsulation
Efficiency (%)

5.27 ± 0.30
4.07 ± 0.15

4.47 ± 0.97
4.19 ± 0.75

84.27 ± 4.39
64.04 ± 15.62

0.0986
0.0139

1.66
1.54
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Despite the low encapsulation efficiencies, both drugs were present at well over the
calculated minimum required doses. For LND, this was 3.13 µg LND/mL microbubble. Similar calculations (outlined in the introduction) for PTX, based on an effective dose of 1 µM
in tissue culture, resulted in the desired minimum dose of 2.77 µg PTX/mL microbubble.
3.2. Dual-Drug LND-and-PTX-Loaded SE61O2
Due to the different molecular weights, sizes, and hydrophilicities of LND and PTX
causing concerns that encapsulating the two drugs together in the same micelle prior to
sonication might result in disproportional drug loading, the investigation used both single
(LP1), and dual (LP2), loaded micelles during fabrication.
3.2.1. Microbubble Size Populations for Dual Drug Loaded SE61O2
Microbubble diameters and concentrations of dual drug loading (two methods) are
compared in Table 3. No significant effect (one-factor MANOVA, p = 0.136) was found
among loading conditions and the bubble size population (mean diameter and total microbubble concentration) after lyophilization. Like single loaded, all microbubble groups
had an average diameter well below the requirement of <6 µm. Light microscopy confirmed these results and representative images are supplied in the Supplementary Materials
(Figure S2). The size distribution profiles are also given in the Supplementary Materials
together with those of unloaded and single-loaded bubbles (Figure S1).
Table 3. Effect of method of dual drug incorporation on microbubble size and concentration, and
acoustic behavior.
Diameter (µm)

Concentration
(Microbubbles/mL)

Maximum
Enhancement (dB)

Dose at Max
(MB/mL × 107 )

Separate Micelle incubation (LP1)

1.74 ± 0.03

2.25 ± 1.19 × 109

18.63 ± 0.05

4.49 ± 0.00

Mixed Micelle incubation (LP2)

1.64 ± 0.02

1.67 ± 0.47 × 109

18.85 ± 0.02

4.46 ± 0.97

3.2.2. In Vitro Acoustic Characterization
The impact of the drug loading method on acoustic behavior can be seen in Figure 4.
Both methods yielded microbubbles with a robust, dose-dependent acoustic response,
and exhibited shadowing at higher doses. For dual loaded SE61O2 microbubbles, the
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maximum enhancement that was achieved was 18.63 ± 0.05 dB for LP1 (separate micelle
incubation) compared with 18.8 ± 0.24 dB for Lp2, comparing favorably with unloaded
bubbles (18.10 ± 0.52), as shown in Table 3.
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and no-drug MBs. These data can be compared favorably with the maximum enhancement
of 18.10 ± 0.52 dB for unloaded microbubbles, as reported above.
3.2.3. Dual Drug Loading Quantification
Effect of Method on Lonidamine Encapsulation
The final drug composition in the microbubbles was analyzed to assess the suitability
to become a carrier for multiple drugs and the impact, if any, of the method of preparation
on the final drug compositions. As reported above, when encapsulating LND alone in the
microbubbles, we have encapsulated 4.19 ± 0.75 µg LND/mL microbubble, representing
an encapsulation efficiency of 1.54%. We noticed an increase in LND loading compared
to LND alone when using separate drug-loaded micelles (LP1) (Table 4); however, no
significant difference (p = 0.09) in loading among the three groups was observed. The result
strongly suggests that co-loading of PTX with LND by either of the two methods did not
deleteriously interfere with the LND loading. In addition, the calculated minimum-required
drug concentration of 3.13 µg LND/mL microbubble was easily met.
Table 4. Effect of method of dual drug incorporation on LND encapsulation.

Separate TPGS micelles (LP1)
Mixed Incubation (LP2)
LND in SE61O2

µg LND/mL Microbubbles

µg LND/g Microbubble

Encapsulation Efficiency (%)

5.01 ± 0.99
4.17 ± 0.43
4.19 ± 0.75

104.85 ± 22.87
87.54 ± 16.41
64.04 ± 15.62

2.42
2.06
1.54

Effect of the Method on Paclitaxel Encapsulation
As shown in Table 5, with PTX, there was a significant difference (p = 0.002) in PTX
drug loading between the three groups. With the use of separate micelles (LP1), the
drug load of PTX was significantly higher (p = 0.035) than with the LP2 microbubbles
in which drugs were together in micelles. Interestingly, the PTX loading of both LP1
and LP2 was found to be significantly greater than that for PTX alone, (p = 0.001 and
p = 0.031 respectively) indicating that the dual loading of LND within the microbubble
shell, irrespective of the micelle loading method, significantly increased the loading of PTX.
This synergistic combination of multiple drugs has been noted before in micelles [44–46].
Although the mechanism behind this phenomenon is not known, one could speculate that
the LND intercalating in the hydrophobic tails caused a more favorable condition for PTX
loading during fabrication but not vice versa. In all cases of PTX loading, as with LND, the
calculated minimum required drug concentration of 2.77 µg PTX/mL microbubble was
easily met in the dual-loaded platforms. These results contrast with LND loading (Table 4),
which showed no increased loading upon the inclusion of PTX.
Table 5. Effect of method of dual drug incorporation on PTX encapsulation.

Separate TPGS micelles (LP1)
Mixed Incubation (LP2)
PTX in SE61O2

µg PTX/mL Microbubbles

µg PTX/g Microbubbles

Encapsulation Efficiency (%)

8.99 ± 0.56
6.50 ± 1.01
4.47 ± 0.97

187.35 ± 8.38
136.51 ± 30.66
84.29 ± 4.39

3.48
2.56
1.66

3.3. In Vitro Imaging
The response of the microbubbles in a clinically relevant ultrasound beam was assessed
using a tissue-mimicking flow phantom and clinical scanner. Samples of LP1-type bubbles
(drugs initially in separate micelles) were chosen since, at the time of analysis, these were
shown to have the highest drug encapsulation and were incorporated into the in vivo
experiments.

3.3. In Vitro Imaging
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The response of the microbubbles in a clinically relevant ultrasound beam was
assessed using a tissue-mimicking flow phantom and clinical scanner. Samples of LP1type bubbles (drugs initially in separate micelles) were chosen since, at the time of
analysis, these were shown to have the highest drug encapsulation and were incorporated
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3.3.2. Stability in the Ultrasound Beam
Operating at a non-destructive MI (0.12), stability curves were constructed from the
flow phantom data, processing a region of interest as described above. Readings taken
every 30 s were converted to normalized enhancement and the resulting plots are shown
in Figure 6. The graphs indicate that the effects of ultrasound on the microbubbles, in the
absence of other factors, would allow circulation with over 80% retained signal, for at least
6 min. For the dual-loaded microbubble, there appears to be a threshold at around 4 min,
after which destruction, as measured by loss of dB returned to the transducer, appears to
accelerate. These values are well within requirements for use of the microbubble to locate
tumors and choose the optimum site to trigger destruction.
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Complete
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4. Conclusions
4. Conclusions
Traditional mono-chemotherapy (use of a single drug) in cancer therapy is now being
Traditional mono-chemotherapy (use of a single drug) in cancer therapy is now being
greatly enhanced by exploiting the synergistic effect of delivering combinations of drugs,
greatly enhanced by exploiting the synergistic effect of delivering combinations of drugs,
especially ones that act by different mechanisms. Further advances are realized by targeted
especially ones that act by different mechanisms. Further advances are realized by
drug delivery and multimodal approaches; however, all these new approaches require
targeted drug delivery and multimodal approaches; however, all these new approaches
the development of suitable drug delivery platforms, which has ushered in the era of
require the development of suitable drug delivery platforms, which has ushered in the era
“combo therapy” [47]. We conclude from this proof-of-concept study that it is possible
of “combo therapy” [47]. We conclude from this proof-of-concept study that it is possible
to successfully develop a multi-modal drug delivery platform that not only acts as an
to successfully develop a multi-modal drug delivery platform that not only acts as an
ultrasound contrast agent (in vitro enhancement up to 18.65 ± 0.05 dB and 18.85 ± 0.02 dB)
ultrasound contrast agent (in vitro enhancement up to 18.65 ± 0.05 dB and 18.85 ± 0.02 dB)
to locate and identify the area to which drug is to be delivered but can also be triggered to
to locate and identify the area to which drug is to be delivered but can also be triggered
deliver a payload of at least two drugs (maximum LND dose of 104.85 ± 22.87 µg LND/g
to deliver a payload of at least two drugs (maximum LND dose of 104.85 ± 22.87 µg LND/g
microbubbles and PTX of 187.35 ± 8.38 µg PTX/g microbubbles) that it has the great
microbubbles and PTX of 187.35 ± 8.38 µg PTX/g microbubbles) that it has the great
advantage of possessing, together with a therapeutic gas (oxygen), in a spatiotemporal
advantage of possessing, together with a therapeutic gas (oxygen), in a spatiotemporal
fashion. This also allows the ability to alleviate radio and chemo-resistance brought about
fashion. This also allows the ability to alleviate radio and chemo-resistance brought about
by hypoxia. We conclude that the resulting dual-loaded microbubbles can be produced
by hypoxia. We conclude that the resulting dual-loaded microbubbles can be produced
within all the constraints for intravenous injection of ultrasound contrast agents such as
within all the constraints for intravenous injection of ultrasound contrast agents such as
size and acoustic response and can achieve therapeutic drug levels. We further conclude
size and acoustic response and can achieve therapeutic drug levels. We further conclude
that when using this method, greater yields are obtained if the two drugs are initially
that when using this method, greater yields are obtained if the two drugs are initially
encapsulated in separate micelles and that inclusion of LND together with PTX significantly
encapsulated in separate micelles and that inclusion of LND together with PTX
enhances the PTX but not the LND loading. Thus, we have provided a methodology to
deliver two drugs in a site-directed fashion, at exactly the same location and point in time,
together with O2 gas.
The overall strategy involved in this work lends itself to various avenues that further
enhance the efficiency of drug incorporation. The original surfactant-stabilized contrast
microbubble showed that stabilization can be explained by the hypothesis of opposing
forces and decreased head-group repulsion in the mixed surfactant system, lending stability
to the microbubble and offering an entire series of Span and Tween molecules as potential
shell components. Later, we replaced Tween with TPGS, further increasing the scope of
the platforms [34,48,49]. The overall strategy involved in this work lends itself to various
avenues to further enhance the efficiency of drug incorporation, which is currently the
major limitation. Future work will evaluate in vivo biodistribution, oxygenation, and
therapeutic gain of this combinatory therapy.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/polym14081568/s1, Figure S1: Representative size distribution
profiles of SE61O2 microbubbles. Unloaded (-•-), Single loaded lonidamine (- -), paclitaxel (-N-),
dual loaded LP1 (-u-), and LP2 (-N-); Figure S2: Light Microscopy images of the SE61O2 MBs taken
under 40× with 1.6× camera magnification, 20 µm size bar shown for reference. (A) Unloaded
SE61O2 (B) LND-loaded SE61O2 (C) PTX loaded SE61O2 . Sizes noted by selected bubbles processes
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using the Olympus cellSens Standard software (Olympus Corporation, Tokyo, Japan); Figure S3:
Light Microscopy images of dual loaded SE61O2 microbubbles taken under 40× with 1.6× camera
magnification, 20 µm size bar shown for reference (A) LP1 (B) LP2. Sizes noted by selected bubbles
processes using the Olympus cellSens Standard software (Olympus Corporation, Tokyo, Japan).
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